BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 38091985)

  • 1. iPSC-derived hypoimmunogenic tissue resident memory T cells mediate robust anti-tumor activity against cervical cancer.
    Furukawa Y; Ishii M; Ando J; Ikeda K; Igarashi KJ; Kinoshita S; Azusawa Y; Toyota T; Honda T; Nakanishi M; Ohshima K; Masuda A; Yoshida E; Kitade M; Porteus M; Terao Y; Nakauchi H; Ando M
    Cell Rep Med; 2023 Dec; 4(12):101327. PubMed ID: 38091985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustainable Tumor-Suppressive Effect of iPSC-Derived Rejuvenated T Cells Targeting Cervical Cancers.
    Honda T; Ando M; Ando J; Ishii M; Sakiyama Y; Ohara K; Toyota T; Ohtaka M; Masuda A; Terao Y; Nakanishi M; Nakauchi H; Komatsu N
    Mol Ther; 2020 Nov; 28(11):2394-2405. PubMed ID: 32710827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. iPSC-Derived Neoantigen-Specific CTL Therapy for Ewing Sarcoma.
    Ishii M; Ando J; Yamazaki S; Toyota T; Ohara K; Furukawa Y; Suehara Y; Nakanishi M; Nakashima K; Ohshima K; Nakauchi H; Ando M
    Cancer Immunol Res; 2021 Oct; 9(10):1175-1186. PubMed ID: 34385178
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [iPSC-derived rejuvenated T-cell therapy for Epstein-Barr virus-associated lymphomas].
    Ando M; Nakauchi H; Komatsu N
    Rinsho Ketsueki; 2018; 59(7):932-938. PubMed ID: 30078805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
    Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
    J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma.
    Harada S; Ando M; Ando J; Ishii M; Yamaguchi T; Yamazaki S; Toyota T; Ohara K; Ohtaka M; Nakanishi M; Shin C; Ota Y; Nakashima K; Ohshima K; Imai C; Nakazawa Y; Nakauchi H; Komatsu N
    Mol Ther; 2022 Feb; 30(2):534-549. PubMed ID: 34628050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing.
    Furukawa Y; Hamano Y; Shirane S; Kinoshita S; Azusawa Y; Ando J; Nakauchi H; Ando M
    Cells; 2022 Jan; 11(2):. PubMed ID: 35053386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustainable Antiviral Efficacy of Rejuvenated HIV-Specific Cytotoxic T Lymphocytes Generated from Induced Pluripotent Stem Cells.
    Miki S; Kawai Y; Nakayama-Hosoya K; Iwabuchi R; Terahara K; Tsunetsugu-Yokota Y; Koga M; Matano T; Kaneko S; Kawana-Tachikawa A
    J Virol; 2022 Mar; 96(6):e0221721. PubMed ID: 35107374
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preservation and redirection of HPV16E7-specific T cell receptors for immunotherapy of cervical cancer.
    Scholten KB; Schreurs MW; Ruizendaal JJ; Kueter EW; Kramer D; Veenbergen S; Meijer CJ; Hooijberg E
    Clin Immunol; 2005 Feb; 114(2):119-29. PubMed ID: 15639645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.
    Bellone S; El-Sahwi K; Cocco E; Casagrande F; Cargnelutti M; Palmieri M; Bignotti E; Romani C; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    J Virol; 2009 Jul; 83(13):6779-89. PubMed ID: 19386711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Unique T-Cell Receptor Amino Acid Sequence Selected by Human T-Cell Lymphotropic Virus Type 1 Tax
    Ishihara Y; Tanaka Y; Kobayashi S; Kawamura K; Nakasone H; Gomyo A; Hayakawa J; Tamaki M; Akahoshi Y; Harada N; Kusuda M; Kameda K; Ugai T; Wada H; Sakamoto K; Sato M; Terasako-Saito K; Kikuchi M; Kimura SI; Tanihara A; Kako S; Uchimaru K; Kanda Y
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28724766
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.
    Santin AD; Hermonat PL; Ravaggi A; Bellone S; Roman JJ; Jayaprabhu S; Pecorelli S; Parham GP; Cannon MJ
    Clin Cancer Res; 2001 Mar; 7(3 Suppl):804s-810s. PubMed ID: 11300476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine.
    Trionfini P; Romano E; Varinelli M; Longaretti L; Rizzo P; Giampietro R; Caroli A; Aiello S; Todeschini M; Casiraghi F; Remuzzi G; Benigni A; Tomasoni S
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Generation of tumor-specific cytotoxic T lymphocytes by stimulation with HPV type 16 E7 peptide-pulsed dendritic cells: an approach to immunotherapy of cervical cancer.
    Schoell WM; Mirhashemi R; Liu B; Janicek MF; Podack ER; Penalver MA; Averette HE
    Gynecol Oncol; 1999 Sep; 74(3):448-55. PubMed ID: 10479508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an HLA-A24-restricted cytotoxic T lymphocyte epitope from human papillomavirus type-16 E6: the combined effects of bortezomib and interferon-gamma on the presentation of a cryptic epitope.
    Morishima S; Akatsuka Y; Nawa A; Kondo E; Kiyono T; Torikai H; Nakanishi T; Ito Y; Tsujimura K; Iwata K; Ito K; Kodera Y; Morishima Y; Kuzushima K; Takahashi T
    Int J Cancer; 2007 Feb; 120(3):594-604. PubMed ID: 17096336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Induced pluripotent stem cell-derived rejuvenated cytotoxic T lymphocyte therapy for Epstein-Barr virus-associated lymphomas: application to clinical practice].
    Ando M
    Rinsho Ketsueki; 2022; 63(9):1310-1315. PubMed ID: 36198557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of tumor-specific cytotoxicity in tumor infiltrating lymphocytes by HPV16 and HPV18 E7-pulsed autologous dendritic cells in patients with cancer of the uterine cervix.
    Santin AD; Bellone S; Palmieri M; Bossini B; Roman JJ; Cannon MJ; Bignotti E; Canè S; Pecorelli S
    Gynecol Oncol; 2003 May; 89(2):271-80. PubMed ID: 12713991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytotoxic T-lymphocyte responses to human papillomavirus type 16 E5 and E7 proteins and HLA-A*0201-restricted T-cell peptides in cervical cancer patients.
    Liu DW; Yang YC; Lin HF; Lin MF; Cheng YW; Chu CC; Tsao YP; Chen SL
    J Virol; 2007 Mar; 81(6):2869-79. PubMed ID: 17202211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generation of individualized immunocompatible endothelial cells from HLA-I-matched human pluripotent stem cells.
    Song C; Wang L; Li Q; Liao B; Qiao W; Li Q; Dong N; Li L
    Stem Cell Res Ther; 2022 Feb; 13(1):48. PubMed ID: 35109922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor T Cells: The Intersection of Stem Cells and Immunotherapy.
    Lahimchi MR; Maroufi F; Maali A
    Cell Reprogram; 2023 Oct; 25(5):195-211. PubMed ID: 37782910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.